Cited by 1,201Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro1

Yasuda, Hisataka, Shima, Nobuyuki, Nakagawa, Nobuaki, Mochizuki, Shin-Ichi, Yano, Kazuki, Fujise, Nobuaki, Sato, Yasushi, Goto, Masaaki, Yamaguchi, Kyoji, Kuriyama, Masayoshi, Kanno, Takeshi, Murakami, Akihiko, Tsuda, Eisuke, Morinaga, Tomonori, Higashio, Kanji·1998·Endocrinology

DOI 10.1210/endo.139.3.5837

Open this paper in CoChat — free account

Abstract

The morphogenesis and remodeling of bone depends on the integrated activity of osteoblasts that form bone and osteoclasts that resorb bone. We previously reported the isolation of a new cytokine termed osteoclastogenesis inhibitory factor, OCIF, which specifically inhibits osteoclast development. Here we report the cloning of a complementary DNA of human OCIF. OCIF is identical to osteoprotegerin (OPG), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. Recombinant human OPG/OCIF specifically acts on bone tissues and increases bone mineral density and bone volume associated with a decrease of active osteoclast number in normal rats. Osteoblasts or bone marrow-derived stromal cells support osteoclastogenesis through cell-to-cell interactions. A single class of high affinity binding sites for OPG/OCIF appears on a mouse stromal cell line, ST2, in response to 1,25-dihydroxyvitamin D3. An anti-OPG/OCIF antibody that blocks the binding abolishes the biological activity of OPG/OCIF. When the sites are blocked with OPG/OCIF, ST2 cells fail to support osteoclastogenesis. These results suggest that the sites are involved in cell-to-cell signaling between stromal cells and osteoclast progenitors and that OPG/OCIF inhibits osteoclastogenesis by interrupting the signaling through the sites.

Integrity signals

Registry

Crossref · 10.1210/endo.139.3.5837

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,736
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,909
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440
SRα Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat
Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M., & Arai, N. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.1.466-472.1988 · Cited by 1,330
A novel domain within the 55 kd TNF receptor signals cell death
Tartaglia, L. A., Ayres, T. M., Wong, G. H., & Goeddel, D. V. (1993) · Cell · doi:10.1016/0092-8674(93)90464-2 · Cited by 1,290
Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule
Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., & Mountz, J. D. (1994) · Science · doi:10.1126/science.7510905 · Cited by 1,108
Modulation of Osteoclast Differentiation
Suda, T., Takahashi, N., & Martin, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004
OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION
Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-123-5-2600 · Cited by 934

Flagged first, then by citations

Show all 33 references

Sorted by citations

Items 301–400 of 999

Current insights into the role of transforming growth factor-β in bone resorption
Fox, S. W., & Lovibond, A. C. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.09.008 · Cited by 90
An introduction to death receptors in apoptosis
Kumar, R., Herbert, P. E., & Warrens, A. Ν. (2005) · International Journal of Surgery · doi:10.1016/j.ijsu.2005.05.002 · Cited by 92
RANKL and RANK as novel therapeutic targets for arthritis
Nakashima, T., & Penninger, J. M. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00016 · Cited by 89
Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis
Reiman, R. M., Gerard, C. J., Campbell, I. L., & Barnum, S. R. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200204)32:4 · Cited by 53
Mechanisms of Bone Fragility: From Osteogenesis Imperfecta to Secondary Osteoporosis
El‐Gazzar, A., & Högler, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020625 · Cited by 89
Osteoclasts and the immune system
Nakashima, T., & Takayanagi, H. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0089-z · Cited by 88
The role of the sympathetic nervous system in controlling bone metabolism
Togari, A., Arai, M., & Kondo, A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.931 · Cited by 88
Effects of Creatine and Resistance Training on Bone Health in Postmenopausal Women
CHILIBECK, P. D., CANDOW, D. G., LANDERYOU, T., KAVIANI, M., & PAUS-JENSSEN, L. (2015) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000000571 · Cited by 87
Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy.
Akatsu, T., Murakami, T., Ono, K., Nishikawa, M., Tsuda, E., Mochizuki, S.-I., Fujise, N., Higashio, K., Motoyoshi, K., Yamamoto, M., et al. (1998) · Bone · doi:10.1016/s8756-3282(98)00141-0 · Cited by 87
Self-citation
Interleukin-32 Promotes Osteoclast Differentiation but Not Osteoclast Activation
Mabilleau, G., & Sabokbar, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004173 · Cited by 88
Regulation of receptor activator of nuclear factor-κB ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures
Lee, S., & Lorenzo, J. (2002) · Bone · doi:10.1016/s8756-3282(02)00804-9 · Cited by 87
Interleukin-18 Up-Regulates Osteoprotegerin Expression in Stromal/Osteoblastic Cells
Makiishi-Shimobayashi, C., Tsujimura, T., Iwasaki, T., Yamada, N., Sugihara, A., Okamura, H., Hayashi, S., & Terada, N. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4380 · Cited by 86
Molecular control of bone remodeling and osteoporosis
Kong, Y., & Penninger, J. M. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00178-9 · Cited by 86
Molecular and Biological Mechanisms of Bone Metastasis
Cecchini, M. G., Wetterwald, A., van der Pluijm, G., & Thalmann, G. N. (2005) · EAU Update Series · doi:10.1016/j.euus.2005.09.006 · Cited by 89
CLONING AND CHARACTERIZATION OF OSTEOCLAST PRECURSORS FROM THE RAW264.7 CELL LINE
Cuetara, B., Crotti, T. N., O’Donoghue, A. J., & McHugh, K. P. (2006) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/0510075.1 · Cited by 88
Changes in Osteoprotegerin/RANKL System, Bone Mineral Density, and Bone Biochemicals Markers in Patients with Recent Spinal Cord Injury
Maı̈moun, L., Couret, I., Mariano‐Goulart, D., Dupuy, A., Micallef, J., Péruchon, E., Ohanna, F., Cristol, J., Rossi, M., & Leroux, J. L. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0048-6 · Cited by 83
Serum Osteoprotegerin as a Determinant of Bone Metabolism in a Longitudinal Study of Human Pregnancy and Lactation
Naylor, K. E., Rogers, A., Fraser, R. B., Hall, V., Eastell, R., & Blumsohn, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030486 · Cited by 84
Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata, N., Kitaura, H., Yoshida, N., & Nakayama, K. (2003) · Bone · doi:10.1016/s8756-3282(03)00213-8 · Cited by 87
Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.
Tomoyasu, A., Goto, M., Fujise, N., Mochizuki, S.-I., Yasuda, H., Morinaga, T., Tsuda, E., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8443 · Cited by 83
Self-citation
Megakaryocyte-mediated inhibition of osteoclast development
Kacena, M. A., Nelson, T., Clough, M. E., Lee, S., Lorenzo, J. A., Gundberg, C. M., & Horowitz, M. C. (2006) · Bone · doi:10.1016/j.bone.2006.05.004 · Cited by 83
Paracrine regulation of osteoclast formation and activity: milestones in discovery.
Martin, T. (2004) · PubMed · Cited by 81
Osteoprotegerin and Osteoclast Differentiation Factor in Tooth Eruption
Wise, G. E., Lumpkin, S. J., Huang, H., & Zhang, Q. (2000) · Journal of Dental Research · doi:10.1177/00220345000790120301 · Cited by 82
Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
Zhang, N., Zhang, Z., Yu, Y., Zhuo, Z., Zhang, G., & Zhang, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00325 · Cited by 82
Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density
Suzuki, K., Kurose, T., Takizawa, M., Maruyama, M., Ushikawa, K., Kikuyama, M., Sugimoto, C., Seino, Y., Nagamatsu, S., & Ishida, H. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.08.006 · Cited by 81
Pharmacological Topics of Bone Metabolism: The Physiological Function of the Sympathetic Nervous System in Modulating Bone Resorption
Togari, A., & Arai, M. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fm0070227 · Cited by 81
Resolvin D2 Restrains Th1 Immunity and Prevents Alveolar Bone Loss in Murine Periodontitis
Mizraji, G., Heyman, O., Dyke, T. E. V., & Wilensky, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00785 · Cited by 81
Reciprocal Control of Expression of mRNAs for Osteoclast Differentiation Factor and OPG in Osteogenic Stromal Cells by Genistein: Evidence for the Involvement of Topoisomerase II in Osteoclastogenesis
Yamagishi, T., Otsuka, E., & Hagiwara, H. (2001) · Endocrinology · doi:10.1210/en.142.8.3632 · Cited by 82
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.
Gravallese, E. M., Galson, D. L., Goldring, S. R., & Auron, P. E. (2001) · Arthritis Research · doi:10.1186/ar134 · Cited by 81
Recent Advances in Osteoclast Biological Behavior
Sun, Y., Li, J., Xie, X., Gu, F., Sui, Z., Zhang, K., & Yu, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.788680 · Cited by 83
Inflammation in periodontal tissues in response to mechanical forces.
Yamaguchi, M., & Kasai, K. (2005) · PubMed · Cited by 80
Mechanisms by which sialylated milk oligosaccharides impact bone biology in a gnotobiotic mouse model of infant undernutrition
Cowardin, C. A., Ahern, P. P., Kung, V. L., Hibberd, M. C., Cheng, J., Guruge, J. L., Sundaresan, V. M., Head, R. D., Barile, D., Mills, D. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821770116 · Cited by 79
Osteoprotegerin in Cardiometabolic Disorders
de Ciriza, C. P., Lawrie, A., & Varo, N. (2015) · International Journal of Endocrinology · doi:10.1155/2015/564934 · Cited by 78
New roles of osteoblasts involved in osteoclast differentiation
Yamashita, T. (2012) · World Journal of Orthopedics · doi:10.5312/wjo.v3.i11.175 · Cited by 82
Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.
Campagnuolo, G., Bolon, B., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10369 · Cited by 78
Osteoporosis in Chronic Obstructive Pulmonary Disease
Sarkar, M. S., Bhardwaj, R., Madabhavi, I., & Khatana, J. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s22803 · Cited by 84
Structure-based development of a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis
Ta, H. M., Nguyen, G. T. T., Jin, H. M., Choi, J., Park, H., Kim, N., Hwang, H., & Kim, K. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011686107 · Cited by 78
Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity
Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77
Self-citation
Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis
Shimizu, S., Asou, Y., Itoh, S., Chung, U., Kawaguchi, H., Shinomiya, K., & Muneta, T. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22941 · Cited by 74
Role of the Osteoclast at the Bone-Implant Interface
Minkin, C., & Marinho, V. C. (1999) · Advances in Dental Research · doi:10.1177/08959374990130011401 · Cited by 76
Relationship between serum RANKL and RANKL in bone
Findlay, D. M., & Atkins, G. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1740-9 · Cited by 76
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor κB legend with bone mineral density in older adults: the Rancho Bernardo Study
Stern, A., Laughlin, G. A., Bergstrom, J., & Barrett-Connor, E. L. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0753 · Cited by 76
1α,25 Dihydroxyvitamin D3 Rapidly Regulates the Mouse Osteoprotegerin Gene Through Dual Pathways
Kondo, T., Kitazawa, R., Maeda, S., & Kitazawa, S. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040604 · Cited by 76
Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation
Atkins, G. J., Haynes, D. R., Geary, S. M., Loric, M., Crotti, T. N., & Findlay, D. M. (2000) · Bone · doi:10.1016/s8756-3282(00)00280-5 · Cited by 76
Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
de Nijs, R. N. J. (2008) · PubMed · Cited by 74
Hyaluronan Increases RANKL Expression in Bone Marrow Stromal Cells Through CD44
Cao, J., Singleton, P. A., Majumdar, S., Boudignon, B. M., Burghardt, A. J., Kurimoto, P., Wronski, T. J., Bourguignon, L., & Halloran, B. P. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041014 · Cited by 79
Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells
Miyashita, T., Kawakami, A., Nakashima, T., Yamasaki, S., Tamai, M., Tanaka, F., Kamachi, M., Ida, H., Migita, K., Origuchi, T., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02534.x · Cited by 74
Canonical Wnt Signaling in Osteoblasts Is Required for Osteoclast Differentiation
Glass, D. A., & Karsenty, G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.015 · Cited by 75
Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation
Ciovacco, W. A., Cheng, Y., Horowitz, M. C., & Kacena, M. A. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22456 · Cited by 75
Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis
Hofbauer, L. C., & Heufelder, A. E. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390152 · Cited by 75
Efficient osteoclast differentiation requires local complement activation
Tu, Z., Bu, H., Dennis, J. E., & Lin, F. (2010) · Blood · doi:10.1182/blood-2010-01-263590 · Cited by 74
Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-Å Resolution
Ito, S., Wakabayashi, K., Ubukata, O., Hayashi, S., Okada, F., & Hata, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106525200 · Cited by 74
A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation
Zhou, H., Kartsogiannis, V., Hu, Y. S., Elliott, J., Quinn, J. M. W., McKinstry, W. J., Gillespie, M. T., & Ng, K. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011554200 · Cited by 76
Decreased Bone Density, Elevated Serum Osteoprotegerin, and β-Cross-Laps in Wilson Disease
Hegedüs, D., Ferencz, V., Lakatos, P. L., Mészáros, S., Lakatos, P. L., Horváth, C., & Szalay, F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.11.1961 · Cited by 75
Muramyl Dipeptide Enhances Osteoclast Formation Induced by Lipopolysaccharide, IL-1α, and TNF-α through Nucleotide-Binding Oligomerization Domain 2-Mediated Signaling in Osteoblasts
Yang, S., Takahashi, N., Yamashita, T., Sato, N., Takahashi, M., Mogi, M., Uematsu, T., Kobayashi, Y., Nakamichi, Y., Takeda, K., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1956 · Cited by 73
Alendronate Therapy May Be Effective in the Prevention of Bone Loss Around Titanium Implants Inserted in Estrogen‐Deficient Rats
Duarte, P. M., Gurgel, B. C. D. V., Sallum, A. W., Filho, G. D. R. N., Sallum, E. A., & Nociti, F. H. (2005) · Journal of Periodontology · doi:10.1902/jop.2005.76.1.107 · Cited by 73
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
Ming, J., Cronin, S. J. F., & Penninger, J. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01283 · Cited by 75
Osteoclastic differentiation and function regulated by old and new pathways
Blair, H. C., & Zaidi, M. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9010-4 · Cited by 74
High Prevalence of Asymptomatic Vertebral Fractures in Chinese Women with Systemic Lupus Erythematosus
Li, E. K., Tam, L., Griffith, J. F., ZHU, T. Y., Li, T. K., Li, M., Wong, K. C., Chan, M. M., Lam, C. W. K., Chu, F. S. K., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081337 · Cited by 71
Macrophage-Elicited Osteoclastogenesis in Response to Bacterial Stimulation Requires Toll-Like Receptor 2-Dependent Tumor Necrosis Factor-Alpha Production
Ukai, T., Yumoto, H., Gibson, F., & Genco, C. (2007) · Infection and Immunity · doi:10.1128/iai.01241-07 · Cited by 77
Mechanisms involved in bone resorption regulated by vitamin D
Nakamichi, Y., Udagawa, N., Suda, T., & Takahashi, N. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.11.005 · Cited by 71
Molecular genetics of too much bone
Janssens, K. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2385 · Cited by 72
Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.
Fahrleitner, A., Prenner, G., Leb, G., Tscheliessnigg, K. H., Piswanger-Sölkner, C., Obermayer-Pietsch, B., Portugaller, H. R., Berghold, A., & Dobnig, H. (2003) · Bone · doi:10.1016/s8756-3282(02)00926-2 · Cited by 71
The dynamic interplay between osteoclasts and the immune system
Nakashima, T., & Takayanagi, H. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.04.004 · Cited by 72
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis
Lipton, A., & Goessl, C. D. (2010) · Bone · doi:10.1016/j.bone.2010.10.161 · Cited by 71
Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women
Arko, B., Preželj, J., Kocijančič, A., Komel, R., & Marc, J. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.08.006 · Cited by 71
Increase in expression of receptor activator of nuclear factor κB at sites of bone erosion correlates with progression of inflammation in evolving collagen‐induced arthritis
Lubberts, E., Oppers‐Walgreen, B., Pettit, A. R., van den Bersselaar, L., Joosten, L. A. B., Goldring, S. R., Gravallese, E. M., & van den Berg, W. B. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10607 · Cited by 70
The effect of environmental cues on the differentiation of myofibroblasts in peritoneal granulation tissue
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
From latency to overt bone metastasis in breast cancer: potential for treatment and prevention
Salvador, F., Lope, A. L., & Gomis, R. R. (2019) · The Journal of Pathology · doi:10.1002/path.5292 · Cited by 73
Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis
Drexler, S. K., Kong, P. L., Wales, J., & Foxwell, B. M. J. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2481 · Cited by 72
Macrophage-Inflammatory Protein-1α Regulates Preosteoclast Differentiationin Vitro
Scheven, B. A. A., Milne, J. S., Hunter, I., & Robins, S. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9909 · Cited by 70
Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.
Tsangari, H., Findlay, D. M., Kuliwaba, J. S., Atkins, G. J., & Fazzalari, N. L. (2004) · Bone · doi:10.1016/j.bone.2004.02.006 · Cited by 69
Osteoblast CFTR Inactivation Reduces Differentiation and Osteoprotegerin Expression in a Mouse Model of Cystic Fibrosis-Related Bone Disease
Stalvey, M. S., Clines, K. L., Havasi, V., McKibbin, C. R., Dunn, L. K., Chung, W. J., & Clines, G. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080098 · Cited by 69
Cloning and Function of Rabbit Peroxisome Proliferator-activated Receptor δ/β in Mature Osteoclasts
Mano, H., Kimura, C., Fujisawa, Y., Kameda, T., Mikiko, W.-M., Kaneko, H., Kaneda, T., Hakeda, Y., & Kumegawa, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8126 · Cited by 67
Osteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00256-8 · Cited by 66
Creatine supplementation for older adults: Focus on sarcopenia, osteoporosis, frailty and Cachexia
Candow, D. G., Chilibeck, P. D., Forbes, S. C., Fairman, C. M., Gualano, B., & Roschel, H. (2022) · Bone · doi:10.1016/j.bone.2022.116467 · Cited by 76
CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway
Villa, I., Mrak, E., Rubinacci, A., Ravasi, F., & GUIDOBONO, F. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00354.2005 · Cited by 70
Signalling in osteoclasts and the role of Fos/AP1 proteins
Wagner, E. F., & Matsuo, K. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.suppl_2.ii83 · Cited by 69
Osteoblasts Provide a Suitable Microenvironment for the Action of Receptor Activator of Nuclear Factor-κB Ligand
Yamamoto, Y., Udagawa, N., Matsuura, S., Nakamichi, Y., Horiuchi, H., Hosoya, A., Nakamura, M., Ozawa, H., Takaoka, K., Penninger, J. M., et al. (2006) · Endocrinology · doi:10.1210/en.2006-0216 · Cited by 67
RANKL Upregulation Associated With Periodontitis and Porphyromonas gingivalis
Wara‐aswapati, N., Surarit, R., Chayasadom, A., Boch, J. A., & Pitiphat, W. (2007) · Journal of Periodontology · doi:10.1902/jop.2007.060398 · Cited by 68
Random walks and cell size
Agutter, P. S., & Wheatley, D. N. (2000) · BioEssays · doi:10.1002/1521-1878(200011)22:11 · Cited by 56
A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function
Brändström, H., Stiger, F., Lind, L., Kahan, T., Melhus, H., & Kindmark, A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00137-7 · Cited by 68
Finding a Toll on the Route: The Fate of Osteoclast Progenitors After Toll-Like Receptor Activation
Souza, P. P. C., & Lerner, U. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01663 · Cited by 67
Circulatory Levels of RANKL, OPG, and Oxidative Stress Markers in Postmenopausal Women With Normal or Low Bone Mineral Density
Azizieh, F. Y., Shehab, D., Al-Jarallah, K. F., Gupta, R., & Raghupathy, R. (2019) · Biomarker Insights · doi:10.1177/1177271919843825 · Cited by 67
Osteoclasts—the innate immune cells of the bone
Wu, Y., Humphrey, M. B., & Nakamura, M. C. (2008) · Autoimmunity · doi:10.1080/08916930701693180 · Cited by 69
Increased Bone Mass in Mice after Single Injection of Anti-receptor Activator of Nuclear Factor-κB Ligand-neutralizing Antibody
Furuya, Y., Mori, K., Ninomiya, T., Tomimori, Y., Tanaka, S., Takahashi, N., Udagawa, N., Uchida, K., & Yasuda, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.246280 · Cited by 68
Self-citation
Osteoprotegerin-Deficient Male Mice as a Model for Severe Alveolar Bone Loss: Comparison With RANKL-Overexpressing Transgenic Male Mice
Koide, M., Kobayashi, Y., Ninomiya, T., Nakamura, M., Yasuda, H., Arai, Y., Okahashi, N., Yoshinari, N., Takahashi, N., & Udagawa, N. (2013) · Endocrinology · doi:10.1210/en.2012-1928 · Cited by 67
Self-citation
Bone remodeling: new aspects of a key process that controls skeletal maintenance and repair
Pogoda, P., Priemel, M., Rueger, J. M., & Amling, M. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1787-y · Cited by 62
Bone lysis and inflammation
Haynes, D. R. (2004) · Inflammation Research · doi:10.1007/s00011-004-1303-z · Cited by 66
Bone remodelling: A signalling system for osteoclast regulation
Filvaroff, E. H., & Derynck, R. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70434-8 · Cited by 66
Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR
Mantovani, A., Locati, M., Polentarutti, N., Vecchi, A., & Garlanda, C. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.1003473 · Cited by 66
Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages
Itonaga, I., Sabokbar, A., Murray, D. W., & Athanasou, N. A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.1.26 · Cited by 66
Pax5-Deficient Mice Exhibit Early Onset Osteopenia with Increased Osteoclast Progenitors
Horowitz, M. C., Xi, Y., Pflugh, D. L., Hesslein, D. G. T., Schatz, D. G., Lorenzo, J., & Bothwell, A. L. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6583 · Cited by 65
p ‐Coumaric acid, a dietary polyphenol ameliorates inflammation and curtails cartilage and bone erosion in the rheumatoid arthritis rat model
Neog, M. K., Pragasam, S. J., Krishnan, M., & Rasool, M. (2017) · BioFactors · doi:10.1002/biof.1377 · Cited by 66
Echistatin Inhibits the Migration of Murine Prefusion Osteoclasts and the Formation of Multinucleated Osteoclast-Like Cells
Nakamura, I., Tanaka, H., Rodan, G. A., & Duong, L. T. (1998) · Endocrinology · doi:10.1210/en.139.12.5182 · Cited by 65
Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells.
Nakagawa, N., Yasuda, H., Yano, K., Mochizuki, S.-I., Kobayashi, N., Fujimoto, H., Shima, N., Morinaga, T., Chikazu, D., Kawaguchi, H., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1601 · Cited by 64
Self-citation
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis
Bado, I., Gugala, Z., Fuqua, S. A. W., & Zhang, X. (2017) · Oncogene · doi:10.1038/onc.2017.94 · Cited by 65
ADRENAL AND GONADAL STEROIDS INHIBIT IL-6 SECRETION BY HUMAN MARROW CELLS
Gordon, C. M., LeBoff, M. S., & Glowacki, J. (2001) · Cytokine · doi:10.1006/cyto.2001.0962 · Cited by 64
Bone effects of vitamin D – Discrepancies between in vivo and in vitro studies
Suda, T., Takahashi, F., & Takahashi, N. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.11.011 · Cited by 66
The orally‐active and selective c‐Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen‐induced arthritis mouse model
Ohno, H., Uemura, Y., Murooka, H., Takanashi, H., Tokieda, T., Ohzeki, Y., Kubo, K., & Serizawa, I. (2007) · European Journal of Immunology · doi:10.1002/eji.200737199 · Cited by 64
Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro
Koch, F. P., Merkel, C., Ziebart, T., Smeets, R., Walter, C., & Al‐Nawas, B. (2010) · Clinical Oral Investigations · doi:10.1007/s00784-010-0477-8 · Cited by 67

Authors: Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., & Higashio, K.
Affiliations: Megmilk Snow Brand (Japan) (JP)
Corresponding author: Higashio, Kanji
ORCID: Yasuda, Hisataka
Sato, Yasushi
Goto, Masaaki
Kanno, Takeshi
Venue: Endocrinology
Publisher: The Endocrine Society
Published: 1998-03
Volume: 139
Issue: 3
Pages: 1329-1337
ISSN: 0013-7227 (ISSN-L)
1945-7170
DOI: 10.1210/endo.139.3.5837
OpenAlex: W2167886526
Cited by: 1,201
References: 33
Citations by year: 2026: 7 · 2025: 13 · 2024: 21 · 2023: 15 · 2022: 21 · 2021: 21 · 2020: 29 · 2019: 36 · 2018: 22 · 2017: 38 · 2016: 22 · 2015: 28 · 2014: 36 · 2013: 54 · 2012: 35
FWCI: 24.00
Type: journal article
Language: en
Open access: closed
Locations: Endocrinology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords: osteoprotegerin, osteoclastogenesis inhibition, TNF receptor superfamily, bone remodeling, bone mineral density, stromal cells, osteoblasts, cell-to-cell signaling, 1,25-dihydroxyvitamin D3, bone resorption, gene cloning
MeSH terms: Amino Acid Sequence, Animals, Cells, Cultured, Cloning, Molecular, Glycoproteins, Humans, Male, Molecular Sequence Data, Osteoclasts, Recombinant Proteins, Bone Density, Bone Remodeling, Rats, Sprague-Dawley, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Mice, Rats, Osteoprotegerin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks